Cargando…
Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan
After the launch of dipeptidyl peptidase-4 (DPP-4), a new oral hypoglycemic drug (OHD), in December 2009, severe hypoglycemia cases were reported in Japan. Although the definite cause was unknown, co-administration with sulfonylureas (SU) was suspected as one of the potential risk factors. The Japan...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834918/ https://www.ncbi.nlm.nih.gov/pubmed/24300302 http://dx.doi.org/10.3390/pharmaceutics4030479 |
_version_ | 1782292066588426240 |
---|---|
author | Kimura, Tomomi Shiosakai, Kazuhito Takeda, Yasuaki Takahashi, Shinji Kobayashi, Masahiko Sakaguchi, Motonobu |
author_facet | Kimura, Tomomi Shiosakai, Kazuhito Takeda, Yasuaki Takahashi, Shinji Kobayashi, Masahiko Sakaguchi, Motonobu |
author_sort | Kimura, Tomomi |
collection | PubMed |
description | After the launch of dipeptidyl peptidase-4 (DPP-4), a new oral hypoglycemic drug (OHD), in December 2009, severe hypoglycemia cases were reported in Japan. Although the definite cause was unknown, co-administration with sulfonylureas (SU) was suspected as one of the potential risk factors. The Japan Association for Diabetes Education and Care (JADEC) released a recommendation in April 2010 to lower the dose of three major SUs (glimepiride, glibenclamide, and gliclazide) when adding a DPP-4 inhibitor. To evaluate the effectiveness of this risk minimization action along with labeling changes, dispensing records for 114,263 patients prescribed OHDs between December 2008 and December 2010 were identified in the Nihon-Chouzai pharmacy claims database. The adherence to the recommended dosing of SU co-prescribed with DPP-4 inhibitors increased from 46.3% before to 63.8% after the JADEC recommendation (p < 0.01 by time-series analysis), while no change was found in those for SU monotherapy and SU with other OHD co-prescriptions. The adherence was significantly worse for those receiving a glibenclamide prescription. The JADEC recommendation, along with labeling changes, appeared to have a favorable effect on the risk minimization action in Japan. In these instances, a pharmacy claims database can be a useful tool to evaluate risk minimization actions. |
format | Online Article Text |
id | pubmed-3834918 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-38349182013-11-21 Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan Kimura, Tomomi Shiosakai, Kazuhito Takeda, Yasuaki Takahashi, Shinji Kobayashi, Masahiko Sakaguchi, Motonobu Pharmaceutics Article After the launch of dipeptidyl peptidase-4 (DPP-4), a new oral hypoglycemic drug (OHD), in December 2009, severe hypoglycemia cases were reported in Japan. Although the definite cause was unknown, co-administration with sulfonylureas (SU) was suspected as one of the potential risk factors. The Japan Association for Diabetes Education and Care (JADEC) released a recommendation in April 2010 to lower the dose of three major SUs (glimepiride, glibenclamide, and gliclazide) when adding a DPP-4 inhibitor. To evaluate the effectiveness of this risk minimization action along with labeling changes, dispensing records for 114,263 patients prescribed OHDs between December 2008 and December 2010 were identified in the Nihon-Chouzai pharmacy claims database. The adherence to the recommended dosing of SU co-prescribed with DPP-4 inhibitors increased from 46.3% before to 63.8% after the JADEC recommendation (p < 0.01 by time-series analysis), while no change was found in those for SU monotherapy and SU with other OHD co-prescriptions. The adherence was significantly worse for those receiving a glibenclamide prescription. The JADEC recommendation, along with labeling changes, appeared to have a favorable effect on the risk minimization action in Japan. In these instances, a pharmacy claims database can be a useful tool to evaluate risk minimization actions. MDPI 2012-09-19 /pmc/articles/PMC3834918/ /pubmed/24300302 http://dx.doi.org/10.3390/pharmaceutics4030479 Text en © 2012 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Article Kimura, Tomomi Shiosakai, Kazuhito Takeda, Yasuaki Takahashi, Shinji Kobayashi, Masahiko Sakaguchi, Motonobu Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan |
title | Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan |
title_full | Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan |
title_fullStr | Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan |
title_full_unstemmed | Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan |
title_short | Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan |
title_sort | quantitative evaluation of compliance with recommendation for sulfonylurea dose co-administered with dpp-4 inhibitors in japan |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834918/ https://www.ncbi.nlm.nih.gov/pubmed/24300302 http://dx.doi.org/10.3390/pharmaceutics4030479 |
work_keys_str_mv | AT kimuratomomi quantitativeevaluationofcompliancewithrecommendationforsulfonylureadosecoadministeredwithdpp4inhibitorsinjapan AT shiosakaikazuhito quantitativeevaluationofcompliancewithrecommendationforsulfonylureadosecoadministeredwithdpp4inhibitorsinjapan AT takedayasuaki quantitativeevaluationofcompliancewithrecommendationforsulfonylureadosecoadministeredwithdpp4inhibitorsinjapan AT takahashishinji quantitativeevaluationofcompliancewithrecommendationforsulfonylureadosecoadministeredwithdpp4inhibitorsinjapan AT kobayashimasahiko quantitativeevaluationofcompliancewithrecommendationforsulfonylureadosecoadministeredwithdpp4inhibitorsinjapan AT sakaguchimotonobu quantitativeevaluationofcompliancewithrecommendationforsulfonylureadosecoadministeredwithdpp4inhibitorsinjapan |